Skip to content

Dyne Therapeutics

US · DYN #2540 by market cap Listed 2020
15.50 -0.53 -3.31%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 3.45 In line with history 59th percentile
5-year average 4.18 · #329 of 514 in Biotechnology
P/E ratio -4.74 In line with history 38th percentile
5-year average -4.67 · forward -4.22
P/S ratio --
5-year average 0.01 · forward 122.07

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Dyne Therapeutics (DYN) 2.90B -4.28 3.12 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value32.07 Economic moatNone UncertaintyVery High

Trading 106.9% below Morningstar's fair value estimate.

Fair value

Dyne Therapeutics Inc receives a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 47% discount to our quantitative fair value estimate of $32.07 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's liquidity strengthens our estimated valuation. Adequate liquidity allows a company to meet short-term obligations, enhancing financial stability and reducing distress risk. Reflecting the firm's liquidity is its median trading volume over the past 60 days, which lies in the top 20% compared with peers globally. Trading volumes are high on shares, which may indicate increased institutional interest in stock ownership. We believe this is a sign that shares could be cheap.

The firm's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's price to cash ratio of 3.0, a core component of valuation, lies in the bottom 30% compared with peers globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. This characteristic further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Dyne Therapeutics discussion 0 comments

Add a comment